AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback